Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 89 clinical trials
Senicapoc and Dehydrated Stomatocytosis

daily in patients with familial dehydrated stomatocytosis caused by the autosomal dominant V282M mutation in the Gardos (KCNN4) channel.

  • 0 views
  • 13 Jun, 2021
  • 1 location
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

is that treatment with HCQ is safe and tolerable in patients with autosomal dominant retinitis pigmentosa (adRP) caused by P23H-RHO, and may arrest progression of retinal degeneration by altering the

genetic testing
corrected visual acuity
pupil dilation
retinopathy
antacids
  • 132 views
  • 21 Mar, 2022
  • 1 location
Retraining Reaching in Cerebellar Ataxia

The purpose of this study is to test for benefits of reinforcement based training paradigm versus standard practice over weeks for improving reaching movements in people with ataxia.

ataxia
stroke
  • 2 views
  • 17 Feb, 2022
  • 1 location
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy

GRIN-related disorders encompass a new group of Inborn Errors of Metabolism according to the recent nosology published by Ferreira et al (Genet Med, 2019). These rare conditions represent a subtype of paediatric encephalopathies leading to intellectual disability, hypotonia, communication deficits and motor impairment (Orphanet entries: 178469, 289266, 101685, for GRIN1, …

  • 0 views
  • 27 Jan, 2021
  • 1 location
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)

safety of lixivaptan in participants with autosomal dominant polycystic kidney disease (ADPKD). Part 1 of the trial is designed to demonstrate the efficacy of lixivaptan in slowing the decline in renal

  • 20 views
  • 15 May, 2022
  • 22 locations
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.

diastolic blood pressure
cyst
systolic blood pressure
  • 340 views
  • 16 May, 2022
  • 132 locations
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE)

This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or …

renal failure
chronic kidney disease
renal disease
nephropathy
  • 195 views
  • 13 Feb, 2022
  • 38 locations
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).

  • 0 views
  • 06 May, 2022
  • 13 locations
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy in subjects who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible subjects will be enrolled and treated …

chronic kidney disease
renal disease
hypertension
tolvaptan
body mass index
  • 16 views
  • 18 May, 2022
  • 9 locations
Statin Therapy in Patients With Early Stage ADPKD

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been

pravastatin
renal disease
glomerular filtration rate
investigational drug
  • 13 views
  • 21 Mar, 2022
  • 1 location